Skip to main content

Table 1 Baseline characteristics of enrolled patients and treatment-emergent adverse event

From: Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial

  TH, n = 3 TL, n = 3 Placebo, n = 3
TH1 TH2 TH3 TL1 TL2 TL3 C1 C2 C3
Age (years) 47 32 31 32 38 33 39 34 43
Sex Male Male Male Male Male Male Female Male Male
National Early Warning Score 2 (NEWS2) 0 0 0 0 0 1 0 0 1
Co-existing disease       Conjunctivitis Thyroid enlargement   
Vital signs abnormality Pre-Hyper-tension No Pre-Hyper-tension Pre-Hyper-tension Pre-Hyper-tension Pre-Hyper-tension Pre-Hyper-tension Pre-Hyper-tension Stage 1 Hyper-tension
Chest X-ray abnormality No Bilateral hilar lymphadenopathy Left lobe pneumonia Right lobe pneumonia No No No No Aorta dilatation
Electrocardiography (ECG) abnormality No No No No No No No No No
Laboratory abnormality         High level of AST/ALT  
Treatment emergent adverse event (TEAE) Right lobe pneumonia Rash maculo-papular Blood lactate Cutaneous candidiasis, myalgia Hepato-biliary disorder
Starting day (duration in days) of TEAE 7* 9 (6) 3 (Unknown) 14 (10; 2) 0 (> 44)
  1. TH treatment high-dose group, TL treatment low-dose group, C placebo group
  2. *The first day TEAE was detected following first scheduled chest X-ray (at days 7); the duration was unknown, but no sign of pneumonia was detected following second scheduled chest X-ray examination (at days 14)